Decoding the human immune system to transform the future of global disease prevention and control

Expert Review of Vaccines

Volumn 15, Issue 10, 2016, Pages 1235-1236

  Koff, Wayne C ^a,c   Schenkelberg, Theodore ^b  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b West Monument Consulting   (United States)

^c The Human Vaccines Project   (United States)

Author keywords

cancer vaccines and immunotherapy; Human vaccines project; immunome; principles of immunogenicity

Indexed keywords

VACCINE; CANCER VACCINE;

DISEASE CONTROL; EDITORIAL; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; COMMUNICABLE DISEASE; DRUG DEVELOPMENT; DRUG EFFECTS; GLOBAL HEALTH; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INTERNATIONAL COOPERATION; NEOPLASM; PROCEDURES; PUBLIC-PRIVATE PARTNERSHIP; TREATMENT FAILURE; VACCINATION;

CANCER VACCINES; COMMUNICABLE DISEASES; DRUG DISCOVERY; GLOBAL HEALTH; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SYSTEM; INTERNATIONAL COOPERATION; NEOPLASMS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; TREATMENT FAILURE; VACCINATION; VACCINES;

EID: 84969772203     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1170600     Document Type: Editorial

References (10)

1. Centers for Disease C, Prevention. Control of infectious diseases. MMWR Morb Mortal Wkly Rep. 1999;48:621–629.
2. J.A.DiMasi, H.G.Grabowski, R.W.Hansen Innovation in the pharmaceutical industry:new estimates of R&D costs. Boston:Tufts Center for the Study of Drug Development. 2014 Nov 18.• One of several studies and methodologies seeking to quantify the costs of R&D.
3. Phase III failure for TeloVac pancreatic cancer vaccine. Genetic Engineering & Biotechnology News; 2013 Jun 3 [cited 2016 Jan22]. Available from:http://www.genengnews.com/gen-news-highlights/phase-iii-failure-for-telovac-pancreatic-cancer-vaccine/81248436/.
4. The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in phase III melanoma clinical trial. FierceBiotech; 2014 Mar 20 [cited 2016 Jan22]. Available from:http://www.fiercebiotech.com/press-releases/investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-does-not-0.
5. R.B.Belshe, P.A.Leone, D.I.Bernstein, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43.
6. World Population Ageing Report. New York (NY):United Nations; 2013 [cited 2016 Jan22]. Available from:http://www.un.org/en/development/desa/population/publications/ageing/WorldPopulationAgeingReport2013.shtml.
7. W.C.Koff, I.D.Gust, S.A.Plotkin. Toward a human vaccines project. Nat Immunol. 2014;15:589–592.•• Summary outcomes of the first working group recommendations on the concept creating a Human Vaccines Project, contains a broad overview of the state of vaccinology.
8. B.Pulendran, S.Li, H.I.Nakaya. Systems vaccinology. Immunity. 2010;33:516–529.
9. A.Sette, R.Rappuoli. Reverse vaccinology:developing vaccines in the era of genomics. Immunity. 2010;33:530–541.
10. M.M.Gubin, X.Zhang, H.Schuster, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–581.